Skip to Content
Go back

Oncology Research

Disease Site

Keywords

Apply

Comprehensive Cancer Center Recent Publications, Oncology:

  1. Duvelisib Eliminates CLL B Cells, Impairs CLL-Supporting Cells, and Overcomes Ibrutinib Resistance in a Xenograft Model.  Chen SS, Barrientos JC, Ferrer G, King-Richards M, Chen YJ, Ravichandran P, Ibrahim M, Kieso Y, Waters S, Kutok JL, Peluso M, Sharma S, Weaver DT, Pachter JA, Rai KR, Chiorazzi N. Clin Cancer Res. 2023 May 15;29(10):1984-1995. doi: 10.1158/1078-0432.CCR-22-2386. PMID: 37071496
  2. Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer. Mirza MR, Chase DM, Slomovitz BM, dePont Christensen R, Novák Z, Black D, Gilbert L, Sharma S, Valabrega G, Landrum LM, Hanker LC, Stuckey A, Boere I, Gold MA, Auranen A, Pothuri B, Cibula D, McCourt C, Raspagliesi F, Shahin MS, Gill SE, Monk BJ, Buscema J, Herzog TJ, Copeland LJ, Tian M, He Z, Stevens S, Zografos E, Coleman RL, Powell MA; RUBY Investigators.N Engl J Med. 2023 Mar 27. doi: 10.1056/NEJMoa2216334. Online ahead of print.PMID: 36972026
  3. CLL stereotyped B-cell receptor immunoglobulin sequences are recurrent in the B-cell repertoire of healthy individuals: Apparent lack of central and early peripheral tolerance censoring.  Vergani S, Bagnara D, Agathangelidis A, Ng AKY, Ferrer G, Mazzarello AN, Palacios F, Yancopoulos S, Yan XJ, Barrientos JC, Rai KR, Stamatopoulos K, Chiorazzi N. Front Oncol. 2023 Mar 17;13:1112879. doi: 10.3389/fonc.2023.1112879. eCollection 2023. PMID: 37007084 Free PMC article.
  4. Mismatch repair deficiency, next-generation sequencing-based microsatellite instability, and tumor mutational burden as predictive biomarkers for immune checkpoint inhibitor effectiveness in frontline treatment of advanced stage endometrial cancer. Hill BL, Graf RP, Shah K, Danziger N, Lin DI, Quintanilha J, Li G, Haberberger J, Ross JS, Santin AD, Slomovitz B, Elvin JA, Eskander RN.Int J Gynecol Cancer. 2023 Apr 3;33(4):504-513. doi: 10.1136/ijgc-2022-004026.PMID: 36750267 Free PMC article. Clinical Trial.
  5. Phase II activity trial of high-dose radiation and chemosensitization in patients with macrometastatic lymph node spread after sentinel node biopsy in vulvar cancer: GROningen INternational Study on Sentinel nodes in Vulvar cancer III (GROINSS-V III/NRG-GY024). Gien LT, Slomovitz B, Van der Zee A, Oonk M.Int J Gynecol Cancer. 2023 Apr 3;33(4):619-622. doi: 10.1136/ijgc-2022-004122.PMID: 36653060 Clinical Trial.
  6. Treatment options for molecular subtypes of endometrial cancer in 2023. Karpel HC, Slomovitz B, Coleman RL, Pothuri B.Curr Opin Obstet Gynecol. 2023 Jun 1;35(3):270-278. doi: 10.1097/GCO.0000000000000855. Epub 2023 Mar 20.PMID: 36943683 Review.
  7. Immunotherapy in endometrial cancer. Mahdi H, Chelariu-Raicu A, Slomovitz BM.Int J Gynecol Cancer. 2023 Mar 6;33(3):351-357. doi: 10.1136/ijgc-2022-003675.PMID: 36878570 Review.
  8. Biomarker-driven therapy in endometrial cancer. Karpel H, Slomovitz B, Coleman RL, Pothuri B.Int J Gynecol Cancer. 2023 Mar 6;33(3):343-350. doi: 10.1136/ijgc-2022-003676.PMID: 36878569 Review.
  9. Randomized phase II trial of farletuzumab plus chemotherapy versus placebo plus chemotherapy in low CA-125 platinum-sensitive ovarian cancer. Herzog TJ, Pignata S, Ghamande SA, Rubio MJ, Fujiwara K, Vulsteke C, Armstrong DK, Sehouli J, Coleman RL, Gabra H, Scambia G, Monk BJ, Arranz JA, Ushijima K, Hanna R, Zamagni C, Wenham RM, González-Martín A, Slomovitz B, Jia Y, Ramsay L, Tewari KS, Weil SC, Vergote IB.Gynecol Oncol. 2023 Mar;170:300-308. doi: 10.1016/j.ygyno.2023.01.003. Epub 2023 Feb 7.PMID: 36758420 Clinical Trial.
  10. Characteristics and Clinical Outcomes of Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Receiving Ibrutinib for ≥5 Years in the RESONATE-2 Study.  Woyach JA, Barr PM, Kipps TJ, Barrientos JC, Ahn IE, Ghia P, Girardi V, Hsu E, Jermain M, Burger JA. Cancers (Basel). 2023 Jan 13;15(2):507. doi: 10.3390/cancers15020507. PMID: 36672456 Free PMC article.  
  11. Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma: A Phase 3 Prospective Externally Controlled Cohort Trial. Liau LM, Ashkan K, Brem S, Campian JL, Trusheim JE, Iwamoto FM, Tran DD, Ansstas G, Cobbs CS, Heth JA, Salacz ME, D’Andre S, Aiken RD, Moshel YA, Nam JY, Pillainayagam CP, Wagner SA, Walter KA, Chaudhary R, Goldlust SA, Lee IY, Bota DA, Elinzano H, Grewal J, Lillehei K, Mikkelsen T, Walbert T, Abram S, Brenner AJ, Ewend MG, Khagi S, Lovick DS, Portnow J, Kim L, Loudon WG, Martinez NL, Thompson RC, Avigan DE, Fink KL, Geoffroy FJ, Giglio P, Gligich O, Krex D, Lindhorst SM, Lutzky J, Meisel HJ, Nadji-Ohl M, Sanchin L, Sloan A, Taylor LP, Wu JK, Dunbar EM, Etame AB, Kesari S, Mathieu D, Piccioni DE, Baskin DS, Lacroix M, May SA, New PZ, Pluard TJ, Toms SA, Tse V, Peak S, Villano JL, Battiste JD, Mulholland PJ, Pearlman ML, Petrecca K, Schulder M, Prins RM, Boynton AL, Bosch ML.JAMA Oncol. 2023 Jan 1;9(1):112-121. doi: 10.1001/jamaoncol.2022.5370.PMID: 36394838 Free PMC article. Clinical Trial.
  12. Consensus opinion from an international group of experts on measurable residual disease in hairy cell leukemia.  Ravandi F, Kreitman RJ, Tiacci E, Andritsos L, Banerji V, Barrientos JC, Bhat SA, Blachly JS, Broccoli A, Call T, Chihara D, Dearden C, Demeter J, Dietrich S, Else M, Epperla N, Falini B, Forconi F, Gladstone DE, Gozzetti A, Iyengar S, Johnston JB, Jorgensen J, Juliusson G, Lauria F, Lozanski G, Parikh SA, Park JH, Polliack A, Quest G, Robak T, Rogers KA, Saven A, Seymour JF, Tadmor T, Tallman MS, Tam CS, Thompson PA, Troussard X, Zent CS, Zenz T, Zinzani PL, Wörmann B, Rai K, Grever M. Blood Cancer J. 2022 Dec 13;12(12):165. doi: 10.1038/s41408-022-00760-z. PMID: 36509740 Free PMC article. Review
  13. How Have Targeted Agents Changed the Treatment Landscape for Elderly Patients with CLL?  Rhodes JM, Barrientos JC, Rai KR. Curr Oncol Rep. 2022 Dec;24(12):1705-1713. doi: 10.1007/s11912-022-01322-z. Epub 2022 Nov 5. PMID: 36334220 Review.
  14. Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study.  Chesney J, Lewis KD, Kluger H, Hamid O, Whitman E, Thomas S, Wermke M, Cusnir M, Domingo-Musibay E, Phan GQ, Kirkwood JM, Hassel JC, Orloff M, Larkin J, Weber J, Furness AJS, Khushalani NI, Medina T, Egger ME, Graf Finckenstein F, Jagasia M, Hari P, Sulur G, Shi W, Wu X, Sarnaik A. J Immunother Cancer. 2022 Dec;10(12):e005755. doi: 10.1136/jitc-2022-005755. PMID: 36600653 Free PMC article. Clinical Trial.
  15. Renal Cell Carcinoma Presenting as Syncope due to Saddle Pulmonary Tumor Embolism. Elajami MK, Mansour E, Bahmad HF, Chaaya G, DeBeer S, Poppiti R, Omarzai Y.Diseases. 2022 Dec 2;10(4):119. doi: 10.3390/diseases10040119.PMID: 36547205 Free PMC article.
  16. The role of immune status, viral co-infections and paraproteinemia in development of venous thromboembolism in HIV. Jou E, Woo M, Subedi A, Chao D, Chow E, Gligich O, Chan ACY, Mohan D, Felsen UR, Billett HH, Raghupathy R.Blood Coagul Fibrinolysis. 2022 Dec 1;33(8):473-475. doi: 10.1097/MBC.0000000000001136. Epub 2022 Jul 22.PMID: 36409924 No abstract available.
  17. Novel ATM Gene c.5644 C > T (p.Arg1882*) Variant Detected in a Patient with Pancreatic Adenocarcinoma and Two Primary Non-Small Cell Lung Adenocarcinomas: A Case Report.  Aljamal AA, Elajami MK, Mansour EH, Bahmad HF, Medina AM, Cusnir M. Diseases. 2022 Dec 1;10(4):115. doi: 10.3390/diseases10040115. PMID: 36547201 Free PMC article.
  18. Factors contributing to delays in initiation of front-line cervical cancer therapy: disparities in a diverse south Florida population. Roy M, Finch L, Kwon D, Jordan SE, Yadegarynia S, Wolfson AH, Slomovitz B, Portelance L, Huang M.Int J Gynecol Cancer. 2022 Nov 7;32(11):1387-1394. doi: 10.1136/ijgc-2022-003475.PMID: 36198435 Free PMC article.
  19. Analysis of MRE11 and Mortality Among Adults With Muscle-Invasive Bladder Cancer Managed With Trimodality Therapy. Magliocco AM, Moughan J, Miyamoto DT, Simko J, Shipley WU, Gray PJ, Hagan MP, Parliament M, Tester WJ, Zietman AL, McCarthy S, Saeed-Vafa D, Xiong Y, Ayral T, Hartford AC, Patel A, Rosenthal SA, Chafe S, Greenberg R, Schwartz MA, Augspurger ME, Keech JA Jr, Winter KA, Feng FY, Efstathiou JA.JAMA Netw Open. 2022 Nov 1;5(11):e2242378. doi: 10.1001/jamanetworkopen.2022.42378.PMID: 36383379 Free PMC article.
  20. Real-world prognostic testing and treatment patterns in CLL/SLL: results from 1462 patients in the informCLL registry.  Mato AR, Ghosh N, Sharman JP, Brander DM, Gutierrez M, Huang Q, Wu LH, Young A, Upasani S, Naganuma M, Barrientos JC. Blood Adv. 2022 Oct 7:bloodadvances.2022008068. doi: 10.1182/bloodadvances.2022008068. Online ahead of print. PMID: 36206191 No abstract available.
  21. Health-related quality of life and treatment satisfaction in Chronic Lymphocytic Leukemia (CLL) patients on ibrutinib compared to other CLL treatments in a real-world US cross sectional study.  Deering KL, Sundaram M, Harshaw Q, Trudeau J, Barrientos JC. PLoS One. 2022 Oct 6;17(10):e0270291. doi: 10.1371/journal.pone.0270291. eCollection 2022. PMID: 36201482 Free PMC article.
  22. Unilateral inguinofemoral lymphadenectomy in patients with early-stage vulvar squamous cell carcinoma and a unilateral metastatic sentinel lymph node is safe. Van der Kolk WL, Van der Zee AGJ, Slomovitz BM, Baldwin PJW, Van Doorn HC, De Hullu JA, Van der Velden J, Gaarenstroom KN, Slangen BFM, Kjolhede P, Brännström M, Vergote I, Holland CM, Coleman R, Van Dorst EBL, Van Driel WJ, Nunns D, Widschwendter M, Nugent D, DiSilvestro PA, Mannel RS, Tjiong MY, Boll D, Cibula D, Covens A, Provencher D, Runnebaum IB, Monk BJ, Zanagnolo V, Tamussino K, Oonk MHM; all GROINSS-V I and II participants.Gynecol Oncol. 2022 Oct;167(1):3-10. doi: 10.1016/j.ygyno.2022.07.017. Epub 2022 Sep 7.PMID: 36085090 Free article.
  23. Cediranib in Combination with Olaparib in Patients without a Germline BRCA1/2 Mutation and with Recurrent Platinum-Resistant Ovarian Cancer: Phase IIb CONCERTO Trial. Lee JM, Moore RG, Ghamande S, Park MS, Diaz JP, Chapman J, Kendrick J, Slomovitz BM, Tewari KS, Lowe ES, Milenkova T, Kumar S, Dymond M, Brown J, Liu JF.Clin Cancer Res. 2022 Oct 3;28(19):4186-4193. doi: 10.1158/1078-0432.CCR-21-1733.PMID: 35917514 Free PMC article.
  24. Repurposed Effect of 177Lu-DOTATATE in the Treatment of Mantle Cell Lymphoma. Elajami MK, Burton LP, Bahmad HF, Chaaya G, Schwartz M.Curr Oncol. 2022 Oct 9;29(10):7552-7557. doi: 10.3390/curroncol29100594.PMID: 36290871 Free PMC article.
  25. Racial and socioeconomic disparities in CLL/SLL: Analysis of SEER data from 2006-2019.  Kittai AS, Huang Y, Bhat SA, Paskett ED, Rogers KA, Barrientos J, Fisher JL, Woyach JA. Blood Adv. 2022 Sep 9:bloodadvances.2022008643. doi: 10.1182/bloodadvances.2022008643. Online ahead of print. PMID: 36083137 No abstract available.
  26. ROS1 altered breast cancers – a distinctive molecular subtype of PR- metastatic breast cancers: Expanding the scope of targeted therapeutics.  Krishnamurthy K, Deb A, Alghamdi S, Schwartz M, Cusnir M, Sriganeshan V, Poppiti R. Breast Dis. 2022;41(1):295-301. doi: 10.3233/BD-220001. PMID: 35634843
  27. Impact of the Types and Relative Quantities of IGHV Gene Mutations in Predicting Prognosis of Patients With Chronic Lymphocytic Leukemia.  Kaufman M, Yan XJ, Li W, Ghia EM, Langerak AW, Rassenti LZ, Belessi C, Kay NE, Davi F, Byrd JC, Pospisilova S, Brown JR, Catherwood M, Davis Z, Oscier D, Montillo M, Trentin L, Rosenquist R, Ghia P, Barrientos JC, Kolitz JE, Allen SL, Rai KR, Stamatopoulos K, Kipps TJ, Neuberg D, Chiorazzi N. Front Oncol. 2022 Jul 12;12:897280. doi: 10.3389/fonc.2022.897280. eCollection 2022. PMID: 35903706 Free PMC article.
  28. Efficacy of niraparib by time of surgery and postoperative residual disease status: A post hoc analysis of patients in the PRIMA/ENGOT-OV26/GOG-3012 study. O’Cearbhaill RE, Pérez-Fidalgo JA, Monk BJ, Tusquets I, McCormick C, Fuentes J, Moore RG, Vulsteke C, Shahin MS, Forget F, Bradley WH, Hietanen S, O’Malley DM, Dørum A, Slomovitz BM, Baumann K, Selle F, Calvert PM, Artioli G, Levy T, Kumar A, Malinowska IA, Li Y, Gupta D, González-Martín A.Gynecol Oncol. 2022 Jul;166(1):36-43. doi: 10.1016/j.ygyno.2022.04.012. Epub 2022 May 9.PMID: 35550709 Free PMC article. Clinical Trial.
  29. Long-term outcomes for ibrutinib-rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial.  Shanafelt TD, Wang XV, Hanson CA, Paietta EM, O’Brien S, Barrientos J, Jelinek DF, Braggio E, Leis JF, Zhang CC, Coutre SE, Barr PM, Cashen AF, Mato AR, Singh AK, Mullane MP, Little RF, Erba H, Stone RM, Litzow M, Tallman M, Kay NE. Blood. 2022 Jul 14;140(2):112-120. doi: 10.1182/blood.2021014960. PMID: 35427411 Free PMC article. Clinical Trial.
  30. Activated CLL cells regulate IL-17F-producing Th17 cells in miR155-dependent and outcome-specific manners.  Jung B, Ferrer G, Chiu PY, Aslam R, Ng A, Palacios F, Wysota M, Cardillo M, Kolitz JE, Allen SL, Barrientos JC, Rai KR, Chiorazzi N, Sherry B. JCI Insight. 2022 Jun 22;7(12):e158243. doi: 10.1172/jci.insight.158243. PMID: 35511436 Free PMC article.
  31. Practice changing cervical cancer clinical trials. Pothuri B, Eskander RN, Randall LM, O’Malley DM, Slomovitz B, Moore KN, Herzog TJ, Coleman RL, Copeland LJ, Monk BJ.Gynecol Oncol. 2022 Jun;165(3):410-412. doi: 10.1016/j.ygyno.2022.03.004. Epub 2022 Apr 20.PMID: 35461731 No abstract available.
  32. The vaginal microbiome is associated with endometrial cancer grade and histology. Hakimjavadi H, George SH, Taub M, Dodds LV, Sanchez-Covarrubias AP, Huang M, Pearson JM, Slomovitz BM, Kobetz EN, Gharaibeh R, Sowamber R, Pinto A, Chamala S, Schlumbrecht MP.Cancer Res Commun. 2022 Jun;2(6):447-455. doi: 10.1158/2767-9764.CRC-22-0075. Epub 2022 Jun 16.PMID: 35928983 Free PMC article.
  33. A randomized phase II trial of everolimus and letrozole or hormonal therapy in women with advanced, persistent or recurrent endometrial carcinoma: A GOG Foundation study. Slomovitz BM, Filiaci VL, Walker JL, Taub MC, Finkelstein KA, Moroney JW, Fleury AC, Muller CY, Holman LL, Copeland LJ, Miller DS, Coleman RL.Gynecol Oncol. 2022 Mar;164(3):481-491. doi: 10.1016/j.ygyno.2021.12.031. Epub 2022 Jan 19.PMID: 35063278 Clinical Trial.
  34. Haemophagocytic lymphohistiocytosis following COVID-19 mRNA vaccination. Wu V, Lopez CA, Hines AM, Barrientos JC. BMJ Case Rep. 2022 Mar 16;15(3):e247022. doi: 10.1136/bcr-2021-247022. PMID: 35296502 Free PMC article.
  35. The mutational landscape of upper gastrointestinal adenocarcinomas- A study of similarities and differences.  Krishnamurthy K, Urioste SN, Cusnir M, Schwartz M, Alghamdi S, Sriganeshan V, Poppiti R. Pathol Res Pract. 2022 Apr;232:153830. doi: 10.1016/j.prp.2022.153830. Epub 2022 Feb 26. PMID: 35240548
  36. Phase II Study of Taselisib in PIK3CA-Mutated Solid Tumors Other Than Breast and Squamous Lung Cancer: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol I. Krop IE, Jegede OA, Grilley-Olson JE, Lauring JD, Mitchell EP, Zwiebel JA, Gray RJ, Wang V, McShane LM, Rubinstein LV, Patton D, Williams PM, Hamilton SR, Kono SA, Ford JM, Garcia AA, Sui XD, Siegel RD, Slomovitz BM, Conley BA, Arteaga CL, Harris LN, O’Dwyer PJ, Chen AP, Flaherty KT.JCO Precis Oncol. 2022 Feb;6:e2100424. doi: 10.1200/PO.21.00424.PMID: 35138919 Free PMC article. Clinical Trial.
  37. Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial. Gershenson DM, Miller A, Brady WE, Paul J, Carty K, Rodgers W, Millan D, Coleman RL, Moore KN, Banerjee S, Connolly K, Secord AA, O’Malley DM, Dorigo O, Gaillard S, Gabra H, Slomovitz B, Hanjani P, Farley J, Churchman M, Ewing A, Hollis RL, Herrington CS, Huang HQ, Wenzel L, Gourley C.Lancet. 2022 Feb 5;399(10324):541-553. doi: 10.1016/S0140-6736(21)02175-9.PMID: 35123694 Free PMC article. Clinical Trial.
  38. Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer. Makker V, Colombo N, Casado Herráez A, Santin AD, Colomba E, Miller DS, Fujiwara K, Pignata S, Baron-Hay S, Ray-Coquard I, Shapira-Frommer R, Ushijima K, Sakata J, Yonemori K, Kim YM, Guerra EM, Sanli UA, McCormack MM, Smith AD, Keefe S, Bird S, Dutta L, Orlowski RJ, Lorusso D; Study 309–KEYNOTE-775 Investigators.N Engl J Med. 2022 Feb 3;386(5):437-448. doi: 10.1056/NEJMoa2108330. Epub 2022 Jan 19.PMID: 35045221 Clinical Trial.
  39. Changing treatments paradigms and role of immunotherapy in recurrent endometrial cancer. Chelariu-Raicu A, Mahdi H, Slomovitz BM.Curr Opin Obstet Gynecol. 2022 Feb 1;34(1):28-35. doi: 10.1097/GCO.0000000000000768.PMID: 34967812 Review.
  40. Gingival Infiltration in Acute Monocytic Leukemia.  Rogers E, Cusnir M. N Engl J Med. 2022 Jan 6;386(1):79. doi: 10.1056/NEJMicm2113297. PMID: 34986288 No abstract available.
Back to top